| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| NRX Pharmaceuticals, Inc. | Chief Financial Officer | Stock Option (right to buy) | 50,000 | $10,000 | $0.2000 | 07 Feb 2025 | Direct |
| Arch Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Common Stock | 10,292 | $2,830 | $0.2750 | 31 Aug 2023 | Direct |
| Arch Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Stock Option (right to buy) | 900,000 | 10 Nov 2022 | Direct | ||
| Arch Therapeutics, Inc. | CHIEF FINANCIAL OFFICER | Warrants (right to buy) | 20,584 | 31 Aug 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| NRXP | NRX Pharmaceuticals, Inc. | 07 Feb 2025 | 1 | $0 | 4 | Chief Financial Officer | 11 Feb 2025, 17:00 |
| NRXP | NRX Pharmaceuticals, Inc. | 18 Nov 2024 | 0 | $0 | 3 | Chief Financial Officer | 22 Nov 2024, 13:44 |
| ARTHQ | Arch Therapeutics, Inc. | 31 Aug 2023 | 2 | +$2,830 | 4 | CHIEF FINANCIAL OFFICER | 08 Sep 2023, 18:47 |
| ARTHQ | Arch Therapeutics, Inc. | 10 Nov 2022 | 1 | $0 | 4 | CHIEF FINANCIAL OFFICER | 10 Nov 2022, 20:49 |
| ARTHQ | Arch Therapeutics, Inc. | 06 Jul 2022 | 3 | $0 | 4 | CHIEF FINANCIAL OFFICER | 08 Jul 2022, 16:57 |
| ARTHQ | Arch Therapeutics, Inc. | 27 Sep 2021 | 1 | $0 | 4 | Chief Financial Officer | 01 Oct 2021, 08:17 |
| ARTHQ | Arch Therapeutics, Inc. | 10 May 2021 | 0 | $0 | 3 | CFO and Treasurer | 10 May 2021, 08:02 |